#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE

FASTLANE study Ph4 RCT on TOFA+NPX vs. PBO+NPX for early active axSpA TOFA arm significantly achieved inactive dse vs. PBO (p=0.006) at wk 16. Similar results seen in secondary efficacy endpts. Interesting results supporting TOFA use AbsOP0241 @RheumNow #EULAR2026 #EULARBest https://t.co/PQYzE1zm0h

RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA -Primary endpoint DAS28-CRP change wk12 -2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01 -ACR20/50/70 + CDAI LDA all improved vs PBO -hsCRP reduction across all dose arms -69% CDAI LDA by wk14 -wk 28 extension shows https://t.co/AMfmSded0D

A new MoA that does not meet it's primary endpoint in RA SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib ACR20 wk12 NOT significantly diff vs PBO ~48.5–61.8% across doses vs 52.3% PBO Secondary BALI 200 mg QD: ACR50: 36.9% vs 18.5% (nominal p=0.0179) Mechanistic https://t.co/hmZ93JisiO

#EULAR2026 OP0228 Is there “something in the air?” Data from US Market Scan: poor quality index was associated with increased risk of #SLE. Although causal inference cannot be deduced, seems an important environmental factor. To check air quality assoc with UV index @RheumNow https://t.co/1FOw7RDA9a

#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN

Which ‘CAR’ to drive in #SLE? Comparison of #CD19 #CAR-T #allogenic vs #Autologous ➡️ comparing #molecular #responses from 2 #lupus studies N=12 Both improved cytokine signatures For #IFN & #neutrophils Results similar not identical ?either #POS0678 #EULAR2026 @RheumNow https://t.co/Lcpv3qJ6tU

Rheumatology Shortage Cliff in Australia & USA Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States. The Australian Rheumatology Association's 2025 Workforce Report warns that the nation faces a significant https://t.co/qVziLM25JR